Alan Russell
Net worth: 799 344 $ as of 2026-05-30
Net worth: 799 344 $ as of 2026-05-30
Alan Russell is the founder of Edgewise Therapeutics, Inc., founded in 2017, where the title held is Director & Chief Scientific Officer.
Former jobs include Associate Director-Muscle Biology & Therapeutics at Cytokinetics, Inc. from 2002 to 2010, and VP & Head-Muscle Metabolism Discovery Performance at GlaxoSmithKline LLC from 2014 to 2017.
Education includes undergraduate and doctorate degrees from the University of Bath.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-03-30 | 23,400 ( 0.02% ) | 799 344 $ | 2026-05-30 |
| Companies | Position | Start |
|---|---|---|
| EDGEWISE THERAPEUTICS, INC. | Founder | 2016-12-31 |
| Companies | Position | End |
|---|---|---|
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Director/Board Member | 2014-08-31 |
| CYTOKINETICS, INCORPORATED | Corporate Officer/Principal | 2010-01-31 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 4 |
|---|---|
Cytokinetics, Inc.
Cytokinetics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes novel drug products | Health Technology |
University of Bath
University of Bath Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Health Technology |
Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. BiotechnologyHealth Technology Develops novel therapies for skeletal muscle diseases | Health Technology |
Select your edition
All financial news and data tailored to specific country editions